Zhao-liang Huang

发表

750 AK119, a CD73 targeting antibody with dual mechanism of action

Na Chen, Xiaoping Jin, T. Zhong, 2021, Journal for ImmunoTherapy of Cancer.

Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen

Wen-feng Zhang, Han Shen, Feng-lin Wu, 2013, Cancer Immunology, Immunotherapy.

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

T. Qu, T. Zhong, Baiyong Li, 2022, Frontiers in Immunology.

Research of fluorescent spectra of oleic acid-stabilized ZnSe nanocrystals based on UV light modification

Zhongchen Bai, Zhengping Zhang, Licai Hao, 2016 .

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity

T. Qu, T. Zhong, Baiyong Li, 2022, Journal for immunotherapy of cancer.

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

T. Zhong, Baiyong Li, Zhao-liang Huang, 2023, mAbs.

Abstract 5526: AK131, an anti-PD1/CD73 bispecific antibody for cancer immune therapy

T. Zhong, Baiyong Li, Zhao-liang Huang, 2022, Cancer Research.

289 Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone

Na Chen, Xiaoping Jin, X. Xia, 2021, Journal for ImmunoTherapy of Cancer.

702 Dual blockade of the PD-1 checkpoint pathway and the adenosinergic negative feedback signaling pathway with a PD-1/CD73 bispecific antibody for cancer immune therapy

N. Chen, Xiaoping Jin, T. Zhong, 2020 .

AK119, A CD73 TARGETING ANTIBODY WITH DUAL MECHANISM OF ACTION

Xiaoping Jin, T. Zhong, X. Xia, 2021 .